abstract |
The present disclosure relates to FcγRIIA binding molecules, eg, humanized monoclonal antibodies capable of inhibiting FcγRIIA activity, and methods of using FcγRIIA binding molecules, eg, in the treatment or prevention of inflammatory, immune-mediated or autoimmune diseases or disorders I will provide a. [Selection] Figure 1-1 |